Brokers Offer Predictions for Kodiak Sciences Q2 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Kodiak Sciences in a research report issued on Monday, March 31st. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.99) for the quarter. HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2025 earnings at ($1.10) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($4.10) EPS and FY2028 earnings at ($2.90) EPS.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.06.

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Monday, December 9th.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $2.40 on Thursday. Kodiak Sciences has a fifty-two week low of $2.19 and a fifty-two week high of $11.60. The company has a market capitalization of $126.30 million, a PE ratio of -0.66 and a beta of 2.26. The company has a 50 day moving average price of $4.44 and a 200-day moving average price of $5.41.

Hedge Funds Weigh In On Kodiak Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after buying an additional 41,987 shares in the last quarter. State Street Corp increased its holdings in shares of Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after acquiring an additional 14,711 shares during the period. Barclays PLC raised its position in shares of Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after acquiring an additional 31,527 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Kodiak Sciences by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock worth $2,007,000 after purchasing an additional 12,783 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.